Filing Flows › Health Care › Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (TSHA) earnings and revenue breakdown
Latest: Q4 2025 · 10-K filed Mar 19, 2026 · Taysha Gene Therapies (TSHA) Q4 2025 earnings results →
Q4 2025 Revenue up 171% year over year to $5.5M · 508¢ of every $1 of revenue lost · operating margin -516.0%
Taysha Gene Therapies made $5.5M in Q4 2025 (+171% Y/Y). Operating margin -516.0%, net loss $27.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.5M in Q4 2025, up 171% year over year.
Operating costs exceeded revenue by $28.3M, an operating margin of -516.0%. Total costs grew 54% against revenue growth of 171%. The fastest-growing cost line was Research & development (+63%). The quarter ended with a net loss of $27.9M.
Operating cash flow was −$26.7M. Non-cash charges added back $299K of depreciation and $3.5M of share-based compensation. Working capital and other items used $2.7M. Capital expenditures of $250K exceeded it, leaving free cash flow of −$27.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 10-K | Mar 19, 2026 | $5.5M | +171% | -516.0% | −$27.9M | −$26.7M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $2.0M | +79% | n/m | −$26.9M | −$20.2M |
| Q1 2025 | 10-Q | May 15, 2025 | $2.3M | -32% | -930.5% | −$21.5M | −$22.0M |
| Q4 2024 | 10-K | Feb 26, 2025 | $2.0M | -44% | -985.8% | −$18.8M | −$18.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Taysha Gene Therapies
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.
In its own words, from its 8-K, filed Aug 11, 2026.
Taysha Gene Therapies against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +171% against the peers' median +29%. Operating margin: -516.0% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Q4 2025 | $5.5M | +171% | -516.0% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Taysha Gene Therapies 10-K on SEC EDGAR · CIK 1806310 · Biological Products, (No Diagnostic Substances)
13F: who owns TSHA and who is buying
More on TSHA
- How Taysha Gene Therapies makes money: revenue by segment
- Taysha Gene Therapies next earnings date and what analysts expect
- Taysha Gene Therapies stock forecast, price target and fair value
- Who owns Taysha Gene Therapies stock: holders, funds and Congress trades
- Taysha Gene Therapies recalls, complaints and regulation
History
Every quarter: Q4 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results